eMedicine Specialties > Pediatrics: General Medicine > Endocrinology

Thyroid Storm: Treatment & Medication

Author: Madhusmita Misra, MD, Assistant in Pediatrics, Mass General Hospital for Children, Harvard Medical School; Assistant Professor of Pediatrics, Fellowship Program Director, Department of Pediatric Endocrinology, Massachusetts General Hospital
Coauthor(s): Abhay Singhal, MD, Assistant Professor of Clinical Pediatrics, Department of Pediatrics, Division of Neonatology, Indiana University School of Medicine; Deborah E Campbell, MD, Professor of Clinical Pediatrics, Albert Einstein College of Medicine; Director, Department of Pediatrics, Division of Neonatology, Weiler Hospital Division of Montefiore Medical Center
Contributor Information and Disclosures

Updated: Jun 4, 2009

Treatment

Medical Care

Patients with thyroid storm should be treated in an ICU setting for close monitoring of vital signs and for access to invasive monitoring and inotropic support, if necessary. Initial stabilization and management of systemic decompensation is as follows:

  • If needed, immediately provide supplemental oxygen, ventilatory support, and intravenous fluids. Dextrose solutions are the preferred intravenous fluids to cope with continuously high metabolic demand.
  • Correct electrolyte abnormalities.
  • Treat cardiac arrhythmia, if necessary.
  • Aggressively control hyperthermia by applying ice packs and cooling blankets and by administering acetaminophen (15 mg/kg orally or rectally every 4 h).
  • Promptly administer antiadrenergic drugs (eg, propranolol) to minimize sympathomimetic symptoms.
  • Correct the hyperthyroid state. Administer antithyroid medications to block further synthesis of thyroid hormones (THs). High-dose propylthiouracil is preferred because of its early onset of action and capacity to inhibit peripheral conversion of T4 to T3 (June 3, 2009: see new FDA warning discussion listed below).
  • The US Food and Drug Administration (FDA) has identified 32 cases (22 adult and 10 pediatric) of serious liver injury associated with propylthiouracil (PTU). Of the adults, 12 deaths and 5 liver transplants occurred, and among the pediatric patients, 1 death and 6 liver transplants occurred. PTU is indicated for hyperthyroidism due to Graves disease. These reports suggest an increased risk for liver toxicity with PTU compared with methimazole. Serious liver injury has been identified with methimazole in 5 cases (3 resulting in death). PTU is considered as second-line drug therapy, except in patients who are allergic or intolerant to methimazole, or for women who are in the first trimester of pregnancy. Rare cases of embryopathy, including aplasia cutis, have been reported with methimazole during pregnancy. The FDA recommends the following criteria be considered for prescribing PTU. For more information, see the FDA Safety Alert.8
    • Reserve PTU use during first trimester of pregnancy, or in patients who are allergic to or intolerant of methimazole.
    • Closely monitor PTU therapy for signs and symptoms of liver injury, especially during the first 6 months after initiation of therapy.
    • For suspected liver injury, promptly discontinue PTU therapy and evaluate for evidence of liver injury and provide supportive care.
    • PTU should not be used in pediatric patients unless the patient is allergic to or intolerant of methimazole, and no other treatment options are available.
    • Counsel patients to promptly contact their health care provider for the following signs or symptoms: fatigue, weakness, vague abdominal pain, loss of appetite, itching, easy bruising, or yellowing of the eyes or skin.
  • Administer iodine compounds (Lugol iodine or potassium iodide) orally or via a nasogastric tube to block the release of THs (at least 1 h after starting antithyroid drug therapy). If available, intravenous radiocontrast dyes such as ipodate and iopanoate can be effective in this regard. These agents are particularly effective at preventing peripheral conversion of T4 to T3.
  • Administer glucocorticoids to decrease peripheral conversion of T4 to T3. This may also be useful in preventing relative adrenal insufficiency due to hyperthyroidism.
  • Treat the underlying condition, if any, that precipitated thyroid storm and exclude comorbidities such as diabetic ketoacidosis and adrenal insufficiency. Infection should be treated with antibiotics.
  • Rarely, as a life-saving measure, plasmapheresis has been used to treat thyroid storm in adults.9

Consultations

  • Endocrinologist
  • Intensivist

Medication

Therapy is aimed at (1) ameliorating hyperadrenergic effects of thyroid hormone (TH) on peripheral tissues with use of beta-blockers (eg, propranolol, labetalol); (2) decreasing further synthesis of THs with antithyroid medications (eg, propylthiouracil [PTU], methimazole); (3) decreasing hormonal release from the thyroid, using iodides; and (4) preventing further TH secretion and peripheral conversion of T4 to T3, using glucocorticoids or iodinated radiocontrast dyes when available.

Antithyroids

These agents belong to the thioureylene (thionamide) class and inhibit synthesis of THs within 1-2 hours. They have no effect on decreasing the release of preformed THs.


Propylthiouracil (PTU, Propyl-Thyracil)

DOC that inhibits synthesis of TH by preventing organification and trapping of iodide to iodine and by inhibiting coupling of iodotyrosines; also inhibits peripheral conversion of T4 to T3, an important component of management. Comatose patients may require administration via NG tube because the agent is available solely as PO preparation; has been successfully administered PR.

Adult

Not first-line agent
Initial: 200-400 mg PO/NG q4-8h
Hyperthyroidism without thyroid storm: 150-450 mg/d PO divided q8h initially
Maintenance: 100-150 mg/d PO divided q8-12h

Pediatric

Not first-line agent
Neonate dose: 5-10 mg/kg/d PO/NG divided q6-8h
Children: 15-20 mg/kg/d PO/NG divided q6-8h initially; higher doses of up to 30-40 mg/kg/d have been successfully used; not to exceed 1200 mg/d
Hyperthyroidism without thyroid storm: 5-7 mg/kg/d PO divided q6-8h initially
Children, maintenance dose: one-third to two-thirds of initial dose q8-12h

Concurrent use with other drugs known to cause bone marrow suppression may cause agranulocytosis; may cause hypothyroidism if used with lithium or potassium iodide; may cause bleeding diathesis if used with anticoagulants (eg, warfarin)

Documented hypersensitivity; liver impairment; pediatric patients (unless allergic or intolerant to methimazole and no other treatment is an option)

Pregnancy

D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus

Precautions

Adverse effects higher in children; aplastic anemia has been described, but leukopenia more often observed; dermatitis, especially urticarial rash; arthritis; arthralgia; lupuslike syndrome; idiosyncratic reactions (eg, hepatitis, hepatic failure) may occur; discontinue upon neutropenia or abnormal LFT results; administer with food to minimize adverse GI effects; risk of serious liver injury, including liver failure and death, has been reported in adults and children by the FDA (carefully consider drug therapy, and if PTU initiated, monitor for symptoms and signs of liver injury, especially during first 6 mo of therapy)


Methimazole (Tapazole)

Inhibits synthesis of TH by preventing organification of iodide to iodine and coupling of iodotyrosines. Although at least 10 times more potent than PTU on a weight basis, it does not inhibit peripheral conversion of T4 to T3. May be used instead of PTU in thyroid storm if iodinated radiocontrast agents are used in conjunction to prevent the conversion of T4 to T3. Comatose patients may require administration via NG tube because agent is available solely as PO preparation.

Adult

Initial dose: 60-120 mg/d PO/NG divided q6-8h
Hyperthyroidism without thyroid storm: 15-60 mg/d PO divided q8-24h initially
Maintenance dose: 10-20 mg/d PO divided q8-24h

Pediatric

Initial dose: 0.5–1 mg/kg/d PO/NG divided q8h
Hyperthyroidism without thyroid storm: 0.5-0.7 mg/kg/d PO divided q8-24h
Maintenance dose: One-third to one-half of initial daily dose divided in 1-3 doses; not to exceed 30 mg/d

Concurrent use with lithium or potassium iodide may cause hypothyroidism; concurrent use with anticoagulants (eg, warfarin) may cause bleeding diathesis

Pregnancy

D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus

Precautions

Adverse effects higher in children; aplastic anemia has been described, but leukopenia observed more often; dermatitis, especially urticarial rash; arthritis; arthralgias; lupuslike syndrome; idiosyncratic reactions (eg, cholestatic jaundice) may occur; liver failure has not been identified; discontinue if neutropenia occurs and if abnormal LFT results persist; administer with food to minimize adverse GI effects; infants born to mothers receiving methimazole have suffered from aplasia cutis

Iodides

Iodides inhibit the release of TH from the thyroid gland. Precede iodide administration with thionamides by at least 1 hour to prevent increased intrathyroidal TH synthesis. Iodinated radiographic contrast dyes that contain ipodate (Oragrafin) or iopanoic acid (Telepaque) have also been used and effectively prevent conversion of T4 to T3. However, their utility in childhood thyroid storm is untested. Another benefit of these radiocontrast agents is the once-daily dosing regimen, as opposed to 3-4 daily doses with iodine-containing oral solutions. Currently, these radiocontrast agents are no longer available in the United States. Lithium carbonate may be used if the patient is hypersensitive to iodine.


Potassium iodide, saturated solution (Pima, SSKI, Thyro-Block)

Used to inhibit TH release from thyroid gland. 1 mL of SSKI contains 1 g of potassium iodide (ie, approximately 50 mg/drop). In adults, sodium iodide 0.25 g IV q6h or 0.5 g IV q12h has also been used successfully.

Adult

2-5 drops (approximately 100-250 mg) PO/NG q6h

Pediatric

Neonates: 100 mg PO/NG q6-8h
Children: Administer as in adults

Use with other potassium-containing agents, potassium-sparing diuretics, and ACE inhibitors may result in hyperkalemia; use with lithium or potassium iodide may precipitate hypothyroidism; administer propylthiouracil before iodides in thyroid storm so that the effect of the propylthiouracil is fully manifested; iodides may inhibit the action of the thiourea drugs because iodine uptake may be initially increased

Documented hypersensitivity; hyperkalemia; pregnant adolescents; impaired renal function, Addison disease

Pregnancy

D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus

Precautions

Hypersensitivity reactions; arrhythmias; GI bleeding; angioedema; administer PO after meals with food or milk or dilute with large quantity of juice, water, or milk


Strong iodine (Lugol Solution)

Contains 100 mg potassium iodide and 50 mg iodine; provided 8 mg iodide/drop.

Adult

10 drops PO tid mixed in water or juice

Pediatric

Administer as in adults

Increases lithium toxicity by producing additive hypothyroid effects; decreased anticoagulant effectiveness of warfarin

Documented hypersensitivity; pulmonary edema; bronchitis; tuberculosis; hyperkalemia

Pregnancy

D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus

Precautions

Prolonged use may result in hypothyroidism; caution in renal failure or GI obstruction

Beta- blockers

These agents are used as the mainstay therapy to control autonomic effects of TH. Beta-blockers also block peripheral conversion of T4 to T3. Esmolol, a short-acting selective beta 1-antagonist, has been used successfully in children, as has labetalol in adults. Beta-blockers should be used with caution in congestive cardiac failure and thyrotoxic cardiomyopathy. In the latter case, they have been known to precipitate cardiac arrest.


Propranolol (Inderal)

DOC most widely used in this group; is a nonselective beta–adrenergic antagonist. Decreases heart rate, myocardial contractility, BP, and myocardial oxygen demand. Often the only adjunctive drug needed to control thyroid storm symptoms.

Adult

20-80 mg/dose PO/NG q4-6h
1-2 mg/dose slow IVP as a single dose; not to exceed administration rate of 1 mg/min; may repeat q10-15min or until symptoms are controlled

Pediatric

Neonates: 2 mg/kg/d PO/NG divided q6-12h
Children: 0.5-4 mg/kg/d PO/NG divided q6h; not to exceed 60 mg/d
0.025-0.15 mg/kg IV over 10 min; may be repeated q10min until hyperdynamic cardiovascular state is improved; not to exceed cumulative dose of 5 mg

Barbiturates, indomethacin, and rifampin may increase propranolol metabolism, lowering serum levels, whereas cimetidine, hydralazine, verapamil, and chlorpromazine may increase serum levels; bioavailability may be increased in Down syndrome, so lower doses may be required in these children; coadministration with catecholamine-depleting drugs such as reserpine may lead to hypotension, bradycardia, and vertigo; may decrease the clearance of theophylline, antipyrine, and lidocaine

Documented hypersensitivity; uncompensated CHF; cardiogenic shock; bradycardia; heart block; pulmonary edema; severe hyperactive airway disease; chronic obstructive pulmonary disease; Raynaud disease

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Most common adverse drug reactions include hypotension, CHF, bradycardia, heart block, CNS depression; nausea, vomiting, constipation, hypoglycemia agranulocytosis; do not administer IV dose faster than 1 mg/min with continuous monitoring; gradually taper dose over 1-2 wk when discontinuing; administer at same time each day; advise patient to inform physician if using concurrently with other adrenergic agonists


Esmolol (Brevibloc)

Beta 1–specific antagonist with a short duration of action.

Adult

500 mcg/kg/min IV infused over 1 min, then 50-100 mcg/kg/min for 4 min; repeat until desired effect; not to exceed 200 mcg/kg/min

Pediatric

Loading dose: 250-500 mcg/kg IV infused over 1 minute; may repeat frequently until desired effect
Maintenance dose: 50-100 mcg/kg/min IV infusion

Aluminum salts, barbiturates, NSAIDs, penicillins, calcium salts, cholestyramine, and rifampin may decrease bioavailability and plasma levels, possibly resulting in decreased pharmacologic effect; cardiotoxicity may increase when administered concurrently with sparfloxacin, astemizole, calcium channel blockers, quinidine, digoxin, or flecainide; toxicity increases when administered concurrently with acetaminophen, clonidine, epinephrine, prazosin, haloperidol, phenothiazines, and catecholamine-depleting agents

Documented hypersensitivity; uncompensated CHF; cardiogenic shock; bradycardia; heart block; Raynaud disease

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Common adverse cardiovascular reactions include hypotension, CHF, bradycardia, and heart block; use with caution in patients with diabetes, as drug can cause hypoglycemia and mask signs and symptoms; bronchospasm; infusion site reactions (eg, phlebitis, skin necrosis) upon extravasation

Glucocorticoids

These agents block conversion of T4 to T3. The use of corticosteroids has been associated with improved survival. Stress doses are required to replace accelerated production and degradation of cortisol induced by TH. If corticosteroids are not administered, acute glucocorticoid deficiency hypothetically could occur because demand may outpace production.


Hydrocortisone succinate (Solu-Cortef)

Provides mineralocorticoid activity and glucocorticoid effects.

Adult

100-200 mg IV q6-8h

Pediatric

5 mg/kg IV q6-8h

Barbiturates or rifampin may decrease effect; potassium-depleting agents (eg, diuretics) may increase risk of hypokalemia; may increase digitalis toxicity secondary to hypokalemia

Documented hypersensitivity; serious infections (excluding meningitis, septic shock); fungal infections; varicella infections.

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

May suppress immune function, but benefits outweigh risks in serious conditions such as thyroid storm; if PO, administer with meals to decrease GI upset; early-onset adverse effects include glucose intolerance, hypertension, agitation, and indigestion; late-onset adverse effects include immune suppression, increased susceptibility to sepsis, adrenal suppression, hypertension, urinary calcium loss, osteopenia, and gastric irritation and bleeding


Dexamethasone (Decadron)

Elicits glucocorticoid effects.

Adult

2 mg PO/IV q6h

Pediatric

0.1-0.2 mg/kg/d PO divided q6-8h

Concurrent use of barbiturates, phenytoin, or rifampin can decrease effects; conversely, dexamethasone decreases effect of salicylates and immunization vaccines

Documented hypersensitivity; serious infections (excluding meningitis, septic shock); fungal infections; varicella infections

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

May suppress immune function, but benefits outweigh risks in serious conditions such as thyroid storm; administer with meals to decrease GI upset; early-onset adverse effects include glucose intolerance, hypertension, agitation, and indigestion; late-onset adverse effects include immune suppression, increased susceptibility to sepsis, adrenal suppression, hypertension, urinary calcium loss, osteopenia, and gastric irritation and bleeding

More on Thyroid Storm

Overview: Thyroid Storm
Differential Diagnoses & Workup: Thyroid Storm
Treatment & Medication: Thyroid Storm
Follow-up: Thyroid Storm
References
[ CLOSE WINDOW ]

References

  1. Aiello DP, DuPlessis AJ, Pattishall EG 3d, Kulin HE. Thyroid storm. Presenting with coma and seizures. In a 3-year-old girl. Clin Pediatr (Phila). - DuPlessis AJ;28(12):571-4. [Medline].

  2. Burch HB, Wartofsky L. Life-threatening thyrotoxicosis. Thyroid storm. Endocrinol Metab Clin North Am. Jun 1993;22(2):263-77. [Medline].

  3. Hasan MK, Tierney WM, Baker MZ. Severe cholestatic jaundice in hyperthyroidism after treatment with 131-iodine. Am J Med Sci. Dec 2004;328(6):348-50. [Medline].

  4. Hirvonen EA, Niskanen LK, Niskanen MM. Thyroid storm prior to induction of anaesthesia. Anaesthesia. Oct 2004;59(10):1020-2. [Medline].

  5. Kadmon PM, Noto RB, Boney CM, et al. Thyroid storm in a child following radioactive iodine (RAI) therapy: a consequence of RAI versus withdrawal of antithyroid medication. J Clin Endocrinol Metab. May 2001;86(5):1865-7. [Medline]. [Full Text].

  6. Al-Anazi KA, Inam S, Jeha MT, Judzewitch R. Thyrotoxic crisis induced by cytotoxic chemotherapy. Support Care Cancer. Mar 2005;13(3):196-8. [Medline].

  7. Lawless ST, Reeves G, Bowen JR. The development of thyroid storm in a child with McCune-Albright syndrome after orthopedic surgery. Am J Dis Child. Sep 1992;146(9):1099-102. [Medline].

  8. FDA MedWatch Safety Alerts for Human Medical Products. Propylthiouracil (PTU). US Food and Drug Administration. Available at http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm164162.htm. Accessed June 3, 2009.

  9. Petry J, Van Schil PE, Abrams P, Jorens PG. Plasmapheresis as effective treatment for thyrotoxic storm after sleeve pneumonectomy. Ann Thorac Surg. May 2004;77(5):1839-41. [Medline].

  10. Knighton JD, Crosse MM. Anesthetic management of childhood thyrotoxicosis and the use of esmolol. Anaesthesia. 1997;52(1):67-70. [Medline].

  11. Misra M, Levitsky LL, Lee MM. Transient hyperthyroidism in an adolescent with hydatidiform mole. J Pediatr. Mar 2002;140(3):362-6. [Medline].

  12. Morrison MP, Schroeder A. Intraoperative identification and management of thyroid storm in children. Otolaryngol Head Neck Surg. Jan 2007;136(1):132-3. [Medline].

  13. Ngo AS, Jung Tan DC. Thyrotoxic heart disease. Resuscitation. Jun 26 2006;[Medline].

  14. Rogers MC, Nichols DG. Thyroid storm. In: Textbook of Pediatric Intensive Care. 3rd ed. Baltimore, MD: Williams & Williams; 1996:1291-95.

  15. Sebe A, Satar S, Sari A. Thyroid storm induced by aspirin intoxication and the effect of hemodialysis: a case report. Adv Ther. May-Jun 2004;21(3):173-7. [Medline].

  16. Tietgens ST, Leinung MC. Thyroid Storm. Medical Clinics of North America. 1995;79(1):169-84. [Medline].

  17. Ureta-Raroque SS, Abramo TJ. Adolescent female patient with shock unresponsive to usual resuscitative therapy. Pediatr Emerg Care. Aug 1997;13(4):274-6. [Medline].

  18. Wartofsky L. Thyroid storm. In: Werner and Ingbar's The Thyroid: A Fundamental and Clinical Text. 6th ed. 1991:871-79.

  19. Wilson BE, Hobbs WN. Case report: pseudoephedrine-associated thyroid storm: thyroid hormone- catecholamine interactions. Am J Med Sci. Nov 1993;306(5):317-9. [Medline].

  20. Yoon SJ, Kim DM, Kim JU, et al. A case of thyroid storm due to thyrotoxicosis factitia. Yonsei Med J. Apr 30 2003;44(2):351-4. [Medline].

[ CLOSE WINDOW ]

Further Reading

[ CLOSE WINDOW ]

Keywords

thyroid storm, thyrotoxic crisis, thyrotoxicosis, thyroid hormones, TH, hypertension, congestive heart failure, hypotension, shock, heat intolerance, tachycardia, delirium, seizures, diarrhea, jaundice, vomiting, abdominal pain, Graves disease, respiratory distress, fatigue, atrial flutter, atrial fibrillation, goiter, McCune-Albright syndrome, juvenile rheumatoid arthritis, Addison disease, type I diabetes, myasthenia gravis, chronic lymphocytic thyroiditis, Hashimoto thyroiditis, systemic lupus erythematosus, chronic active hepatitis, nephrotic syndrome

[ CLOSE WINDOW ]

Contributor Information and Disclosures

Author

Madhusmita Misra, MD, Assistant in Pediatrics, Mass General Hospital for Children, Harvard Medical School; Assistant Professor of Pediatrics, Fellowship Program Director, Department of Pediatric Endocrinology, Massachusetts General Hospital
Madhusmita Misra, MD is a member of the following medical societies: Endocrine Society and Lawson-Wilkins Pediatric Endocrine Society
Disclosure: Tercica Grant/research funds Principal investigator; Ipsen Consulting fee Review panel membership

Coauthor(s)

Abhay Singhal, MD, Assistant Professor of Clinical Pediatrics, Department of Pediatrics, Division of Neonatology, Indiana University School of Medicine
Abhay Singhal, MD is a member of the following medical societies: American Academy of Pediatrics
Disclosure: Nothing to disclose.

Deborah E Campbell, MD, Professor of Clinical Pediatrics, Albert Einstein College of Medicine; Director, Department of Pediatrics, Division of Neonatology, Weiler Hospital Division of Montefiore Medical Center
Deborah E Campbell, MD is a member of the following medical societies: American Academy of Pediatrics, American Association for the Advancement of Science, American Medical Association, National Perinatal Association, New York Academy of Medicine, and New York Academy of Sciences
Disclosure: Nothing to disclose.

Medical Editor

Phyllis W Speiser, MD, Chief of Pediatric Endocrinology, Schneider Children's Hospital; Professor of Pediatrics, New York University School of Medicine
Phyllis W Speiser, MD is a member of the following medical societies: American Association of Clinical Endocrinologists, Endocrine Society, Lawson-Wilkins Pediatric Endocrine Society, and Society for Pediatric Research
Disclosure: Nothing to disclose.

Pharmacy Editor

Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine
Disclosure: Pfizer Inc Stock Investment from financial planner; Avanir Pharma Stock Investment from financial planner ; WebMD Salary and stock Employment and investment from financial planner

Managing Editor

Lynne Lipton Levitsky, MD, Chief, Pediatric Endocrine Unit, Massachusetts General Hospital; Associate Professor, Department of Pediatrics, Harvard University Medical School
Lynne Lipton Levitsky, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, American Diabetes Association, American Pediatric Society, Endocrine Society, Lawson-Wilkins Pediatric Endocrine Society, and Society for Pediatric Research
Disclosure: Pfizer Grant/research funds P.I.; Tercica Grant/research funds PI, also occasional consultant

CME Editor

Merrily P M Poth, MD, Professor, Department of Pediatrics and Neuroscience, Uniformed Services University of the Health Sciences
Merrily P M Poth, MD is a member of the following medical societies: American Academy of Pediatrics, Endocrine Society, and Lawson-Wilkins Pediatric Endocrine Society
Disclosure: Nothing to disclose.

Chief Editor

Stephen Kemp, MD, PhD, Professor, Department of Pediatrics, Section of Pediatric Endocrinology, University of Arkansas and Arkansas Children's Hospital
Stephen Kemp, MD, PhD is a member of the following medical societies: American Academy of Pediatrics, American Association of Clinical Endocrinologists, American Pediatric Society, Endocrine Society, Phi Beta Kappa, Southern Medical Association, and Southern Society for Pediatric Research
Disclosure: Genentech, Inc. Honoraria Speaking and teaching; Pfizer, Inc. Honoraria Consulting

RELATED MEDSCAPE ARTICLES
Articles
 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.